Get the Stockscreener App
5.69
6.41%
-0.39
After Hours:
5.70
0.010
+0.18%
Cvrx Inc stock is traded at $5.69, with a volume of 191.52K.
It is down -6.41% in the last 24 hours and down -22.16% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$6.08
Open:
$6.11
24h Volume:
191.52K
Relative Volume:
0.72
Market Cap:
$149.14M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-2.1036
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
-14.31%
1M Performance:
-22.16%
6M Performance:
-24.23%
1Y Performance:
-61.29%
1-Day Range:
$5.665
$6.22
1-Week Range:
$5.665
$7.03
52-Week Range:
$4.2993
$15.41
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
5.69 | 159.36M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx Q4 Earnings Call Highlights - MarketBeat
CVRX: Revenue and margin growth set the stage for accelerated expansion with new reimbursement and clinical trial catalysts - TradingView
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: CVRx Q4 2025 sees stock surge despite earnings miss - Investing.com
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Bitget
CVRx (NASDAQ:CVRX) Announces Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
CVRx: Fourth Quarter Financial Highlights - Bitget
CVRx (CVRX) Q4 2025 Earnings Call Transcript - The Globe and Mail
CVRx: Q4 Earnings Snapshot - WKYC
CVRx's Earnings: A Preview - Benzinga
CVRX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving CVRx Inc. - Business Wire
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Growth Value: Should you buy the dip on CVRx IncJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Returns Recap: Whats the beta of CVRx Inc stockJuly 2025 Review & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
CVRx showcases Barostim integration at heart failure program - Traders Union
S P Trends: Whats the beta of CVRx Inc stockJuly 2025 Retail & Daily Profit Maximizing Tips - baoquankhu1.vn
Income Plays: How correlated is CVRX to the S P5002025 Trading Recap & Verified Entry Point Signals - baoquankhu1.vn
Understanding the Setup: (CVRX) and Scalable Risk - Stock Traders Daily
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
CVRx INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 - The Manila Times
Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - marketscreener.com
Setup Watch: Will CVRX stock recover faster than peersWeekly Trend Recap & Weekly High Potential Stock Alerts - mfd.ru
Swing Trade: Will CVRx Inc announce a stock splitMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn
CVRx: Barostim gains new CPT codes for 2026 - Traders Union
Gains Recap: Whats the fair value of CVRX stockMarket Activity Summary & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
CVRx (CVRX) to Release Earnings on Tuesday - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. – CVRX - ChartMill
CVRx supports MU Health with first Barostim implant - Traders Union
The Truth About CVRx Inc: Wall Street’s Sleeping Giant You’re Not Watching (Yet) - AD HOC NEWS
CVRx Kicks Off One Of The Largest Heart Device Trials In History - Sahm
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Downgrade Watch: Should value investors consider CVRXWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途资讯
CVRx’s stock up as heart failure device to be trialled in expanded patient group - Yahoo Finance
CVRx launches major heart failure trial to expand Barostim therapy reach - Investing.com Australia
CVRx Initiates BENEFIT-HF Trial; Q4 Financial Report Coming Soon - RTTNews
CVRx stock rises after announcing major heart failure clinical trial By Investing.com - Investing.com India
Cvrx Announces Initiation Of Benefit-Hf, A Landmark Heart Failure Trial - TradingView
CVRx stock rises after announcing major heart failure clinical trial - Investing.com
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart - GlobeNewswire
Activity Recap: Does Amarin Corporation plc Depositary Receipt have declining or rising EPSWall Street Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
The Technical Signals Behind (CVRX) That Institutions Follow - Stock Traders Daily
Movement Recap: Whats the beta of CVRx Inc stock2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Fundamentals Check: Whats the beta of CVRx Inc stockBuy Signal & Smart Money Movement Tracker - baoquankhu1.vn
AI Stocks: What is the earnings history of CVRx IncQuarterly Market Review & AI Forecasted Stock Moves - baoquankhu1.vn
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):